Validating DSP counts with multiplex immunofluorescence, they then identified an Interleukin-2 (IL2) axis between tumor and stroma compartments, and hence IL2 receptor alpha (CD25) as a potential predictive biomarker of response. This evidence concerns the gene IL2 and neoplasm.